Identification of the genetic basis of pediatric neurogenetic disorders at a tertiary referral hospital in Indonesia: Contribution of whole exome sequencing

PLoS One. 2023 Oct 25;18(10):e0293113. doi: 10.1371/journal.pone.0293113. eCollection 2023.

Abstract

Background: Neurogenetic disorders (NGDs) are complex Mendelian disorders that affect the neurological system. A molecular diagnosis will provide more information about pathophysiology, prognosis, and therapy, including future genetic therapy options. Whole-Exome Sequencing (WES) can rapidly discover the genetic basis in NGDs.

Objective: The purpose of this study was to assess the WES results and its value in diagnosing pediatric NGDs, especially those with unspecified clinical features.

Methods: A retrospective chart review was performed from May 2021- February 2023 in Dr. Sardjito General Hospital, a tertiary referral hospital in Yogyakarta, Indonesia. WES proband only was conducted on children aged 0 to 17 years old who met one or more of the following criteria: (1) epileptic encephalopathy and familial epilepsy; (2) complex neurodevelopmental phenotypes; (3) leukodystrophy; (4) movement disorders; and (5) neurocutaneous disorder. The WES was conducted in the certified laboratory, 3Billion, in Seoul, Korea.

Results: The diagnosis yield of WES in our study was 45% (9/20). We identified nine positive results, including eight pathogenic single nucleotide variants (SNVs) in 8 genes (KCNQ2, ARSA, UBE3A, IRF2BPL, ATM, MECP2, TSC2, and NF1), and one variant with uncertain significance (VUS) in the ADK gene that has not been able to explain the observed clinical features. Of the nine patients with positive WES results, five had missense mutations, three frameshift mutations, and one nonsense mutation. Additionally, we identified two suggestive copy number variants (CNVs) in 15q11.2q13.1 and 1p31.3.

Conclusions: Whole-Exome Sequencing is an essential diagnostic tool for pediatric NGDs, especially those with unspecified clinical features. It ends multi-year diagnostic odysseys, provides personalized medicine therapy, and optimizes genetic counselling for these families.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Carrier Proteins*
  • Child
  • Child, Preschool
  • Exome Sequencing
  • Humans
  • Indonesia
  • Infant
  • Infant, Newborn
  • Nuclear Proteins*
  • Phenotype
  • Retrospective Studies
  • Tertiary Care Centers

Substances

  • IRF2BPL protein, human
  • Carrier Proteins
  • Nuclear Proteins

Grants and funding

This study was supported by grants from the Ministry of Research and Technology/National Research and Innovation Agency of the Republic of Indonesia to Agung Triono under contract numbers 018/E5/PG.02.00.PT/2022 and Kristy Iskandar under contract numbers 2137/UN1/DITLIT/Dit-Lit/PT.01.03/2023 and. Url of funder website: https://bima.kemdikbud.go.id. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.